Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis

Clin Rheumatol. 1993 Sep;12(3):318-24. doi: 10.1007/BF02231572.

Abstract

Tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF), all of endothelial origin and active in the haemostasis, were analysed in 74 patients with rheumatoid arthritis. The concentrations were related to extra-articular disease and to the incidence of thromboembolic events (TE) registered in a 2-year follow-up period. Patients with extra-articular disease had a significant increase in PAI-1 activity and reduced tPA release in the venous occlusion test. von Willebrand factor, PAI-1 and also haptoglobin and triglycerides were significantly increased in the group of patients who later suffered from TE. In a multiple regression model, in which cholesterol, triglycerides and lipoprotein (a) showed significant association with TE, vWF had the strongest additive explanatory value. No distinct acute phase pattern of PAI-1 was found in any patient subgroup.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Arthritis, Rheumatoid / blood*
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / physiopathology
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / blood*
  • Regression Analysis
  • Thromboembolism / epidemiology
  • Thromboembolism / etiology
  • Tissue Plasminogen Activator / blood*
  • von Willebrand Factor / analysis*

Substances

  • Plasminogen Activator Inhibitor 1
  • von Willebrand Factor
  • Tissue Plasminogen Activator